Statements (110)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
none reported
|
| gptkbp:awards |
various industry awards
|
| gptkbp:business_model |
research and development driven
|
| gptkbp:ceo |
gptkb:Armando_Anido
|
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:Canada gptkb:United_States gptkb:Zygel ongoing Phase 1 Phase 2 Phase 3 diverse populations multiple stages Phase 2b multiple sites published in peer-reviewed journals published in journals cannabinoid therapies presented at conferences announced publicly Phase 2a open for participants Phase 3b non-psychoactive cannabinoids transdermal delivery systems |
| gptkbp:collaboration |
academic institutions
research organizations |
| gptkbp:collaborations |
gptkb:international_partners
academic institutions |
| gptkbp:community_engagement |
gptkb:healthcare_professionals
gptkb:scientific_community patient advocacy patient advocacy groups |
| gptkbp:community_outreach |
gptkb:educational_programs
|
| gptkbp:community_support |
local initiatives
|
| gptkbp:feedback |
integrated into development
|
| gptkbp:financial_reports |
gptkb:reports
quarterly earnings quarterly updates |
| gptkbp:financials |
publicly traded
|
| gptkbp:focus |
cannabinoid-based therapies
|
| gptkbp:founded |
gptkb:2007
|
| gptkbp:funding |
grants
investments public offerings |
| gptkbp:future_plans |
expand product line
|
| gptkbp:grants |
awarded by government agencies
|
| gptkbp:has_advisory_board |
experts in cannabinoid research
|
| gptkbp:headquarters |
gptkb:Devon,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zynerba Pharmaceuticals
|
| gptkbp:instruction_set |
multiple candidates
|
| gptkbp:invention |
patents
licensing agreements trademarks patents filed |
| gptkbp:investment |
gptkb:venture_capital
regular updates institutional investors Venture capital firms transparent communication |
| gptkbp:investment_focus |
pediatric patients
adult patients |
| gptkbp:investment_strategy |
volatile
|
| gptkbp:leadership |
gptkb:Board_of_Directors
executive team experienced management team |
| gptkbp:market |
conducted regularly
|
| gptkbp:market_cap |
small-cap
|
| gptkbp:marketing_strategy |
focused on niche markets
|
| gptkbp:mission |
develop innovative therapies
|
| gptkbp:number_of_employees |
100-200
500+ 200-500 50-100 growing team |
| gptkbp:partnership |
gptkb:Canopy_Growth_Corporation
Aphria Inc. |
| gptkbp:partnerships |
various research institutions
biotechnology firms |
| gptkbp:product |
gptkb:Zynerba's_cannabinoid_formulations
ongoing efforts Zygel (CBD gel) |
| gptkbp:products |
gptkb:Zygel
|
| gptkbp:publications |
frequent contributions
|
| gptkbp:regulatory_compliance |
gptkb:FDA
multiple applications |
| gptkbp:research_areas |
neurology
psychiatry neurological disorders pain management psychiatric disorders |
| gptkbp:research_focus |
gptkb:epilepsy
gptkb:fragile_X_syndrome chronic pain autism spectrum disorder cannabinoid therapies |
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:stock_symbol |
ZYNE
|
| gptkbp:stockholders |
individual and institutional
|
| gptkbp:sustainability_practices |
environmentally responsible
|
| gptkbp:target_market |
neurological disorders
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
positive results
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:vision |
improve patient quality of life
|
| gptkbp:website |
zynerba.com
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
4
|